Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

All forms of Brexit will negatively impact the UK National Health Service (NHS), but the prospect of a no-deal Brexit presents by far the worst scenario, with negative effects on the health care workforce, NHS financing, availability of medicines and vaccines, sharing of information, and medical research, according to a new health policy review published in The Lancet and co-authored by Oxford's Dr Nick Fahy.

Hospital Staff In Busy Lobby Area Of Modern Hospital © Shutterstock

While the withdrawal agreement negotiated between the UK government and the EU (but not agreed by parliament) offers a more positive scenario compared with a no-deal Brexit, there are serious concerns about the negative impact of Brexit on the NHS beyond the transition period, when the backstop or arrangements envisaged in the political declaration on the future relationship would come into force.

Under either the backstop or political declaration scenarios, the impact of Brexit on the NHS is only slightly less harmful than the no-deal scenario, though the exact impacts vary.

In the new analysis, the authors, who are leading experts in public health and law, use the available legal and political texts on four Brexit scenarios to assess the likely impact on 15 specific aspects of the UK health service.

Read more (University of Oxford website)

Similar stories

Human challenge trial launches to study immune response to COVID-19

Clinical Trials Coronavirus COVID-19 General

Though the COVID-19 pandemic has now been active for a year, not much is known about what happens when people who have already had COVID-19 are infected for a second time.

Risk of rare blood clotting higher for COVID-19 than for vaccines

Coronavirus COVID-19 Research

COVID-19 leads to a several-times higher risk of cerebral venous thrombosis (CVT) blood clots than current COVID-19 vaccines.

Alternating vaccines trial expands to include two additional vaccines

Clinical Trials Coronavirus COVID-19 General

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.

Oxford medical students launch flagship raffle in aid of NHS heroes and lifesaving medical equipment

General

Tingewick, a society formed of medical students from Oxford University, are hosting a virtual charity raffle. With over 70 amazing prizes, ranging from Truck festival tickets to restaurant vouchers to bags of books and even a bike, the raffle is an exciting way to celebrate lockdown lifting by supporting many wonderful Oxfordshire businesses whilst raising lots of money for charity.

Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19

Clinical Trials Coronavirus COVID-19 Research

Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants.